1. Federal regulators require Novavax to complete another trial for Covid-19 vaccine approval. 2. This follows an earlier delay in approval, impacting NVAX's market prospects.
The requirement for an additional clinical trial suggests delays in revenue generation. Historically, similar situations have led to stock declines for biotech firms.
The news directly affects NVAX's operational timeline and market confidence, influencing stock price.
Approval delays typically influence stock performance quickly as investors react to regulatory news.